Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Chronic hepatitis B virus HBV infection is a major global health issue that can lead to serious liver problems such as cirrhosis, liver cancer, and death. This observational study aims to gather detailed information from a broad group of Chinese patients with chronic HBV infection to better understand the factors that influence disease outcomes. The study involves creating a comprehensive database of clinical, epidemiological, biological, virological, immunologic, and treatment-related data from patients with chronic HBV infection. There are no drug interventions instead, participants are monitored as part of this long-term cohort. Participants will be followed over many years, with researchers tracking outcomes like loss of hepatitis B antigens, development of cirrhosis, liver failure, liver cancer, and mortality. Regular assessments will collect relevant health information to help identify the factors linked to disease progression. The study is planned to continue until 2030, providing extensive long-term data on chronic HBV infection.
Actively Recruiting
Researchers are evaluating a new telemedicine-enabled integrated care model led by rural doctors to reduce cardiovascular and cerebrovascular events in elderly adults aged 65 years and older who are at high risk of stroke in rural China. This cluster randomized controlled trial compares this innovative care approach with enhanced usual care to address the high stroke burden in rural areas. The study aims to improve clinical outcomes by bridging gaps in rural stroke management over a 36-month period. Participants in the intervention group will receive care supported by a digital health platform that provides clinical decision support, remote specialist consultations, personalized medication adjustments, monthly monitoring, and structured patient education delivered by rural doctors. The control group will receive enhanced usual care that includes standardized training for rural doctors but without the digital platform. The study will enroll 2510 participants across 39 village clinics randomized to either group and will follow them for 36 months. During the study, participants will have regular monitoring and follow-up with rural doctors who utilize the digital platform or provide enhanced usual care. Researchers will assess outcomes including a composite measure of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months. Additional measures include recurrent stroke rates, mortality, bleeding events, risk score changes, medication adherence, and risk factor control. The study includes comprehensive follow-up and data collection to evaluate the interventions impact on participants health over three years.
Actively Recruiting
Researchers are investigating acute aortic syndrome AAS, a serious and life-threatening heart condition where inflammation plays a significant role in its development and progression. This large observational study involves 20 cardiovascular centers in China collaborating to understand inflammatory responses and anti-inflammatory treatments in patients undergoing surgery for AAS. The study aims to assess how inflammation and anti-inflammatory strategies affect patient outcomes after surgery, including complications and survival. The study enrolls adult patients who have undergone surgery for AAS, which includes various types of aortic injuries such as dissection, penetrating ulcers, or hematomas. Participants may have received medical therapy, open surgery, endovascular repair, or hybrid procedures, sometimes combined with other cardiac surgeries. Data about their inflammatory responses and clinical results are collected through designed forms and analyzed using statistical software. This observational study began in 2016 and will continue enrolling patients until 2040. Participants will be followed over time to evaluate key outcomes like severe inflammatory reactions within 7 days after surgery and operative mortality within 30 days. Researchers will also monitor other complications such as organ dysfunction, stroke, kidney injury, infections, bleeding, and length of intensive care stay. The study gathers detailed information through clinical data collection and monitors these outcomes to better understand and improve management for patients with AAS over the long term.
Actively Recruiting
Chronic hepatitis B virus HBV infection is a significant global health concern. Researchers are investigating the clinical outcomes of patients with chronic hepatitis B CHB who are negative for hepatitis B e antigen HBeAg and fall into an indeterminate phase, meaning their blood test results do not clearly fit into the usual CHB phases. This study aims to understand the health progression of these patients, whose outcomes are not well known, which can help improve individual patient management. Participants are divided into two groups one group will be observed with regular monitoring every six months, and the other group will receive first-line antiviral treatments such as entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide, or peginterferon. The study is a prospective, observational cohort design conducted across multiple centers, aiming to follow patients over a long period. During the study, participants will have regular assessments to track key outcomes including the occurrence of liver cancer hepatocellular carcinoma and the clearance rate of hepatitis B surface antigen HBsAg over 240 weeks about 4.5 years. Researchers will monitor liver health, viral levels, and other clinical markers to understand disease progression. The study is led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and will continue until May 2028.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a large-scale, multicenter observational study called the Dongzong Cardiovascular Bio-imaging Registry Study. This project aims to build a comprehensive database combining genetic, biological, environmental, imaging, and clinical data to better understand how genes and living environments influence lung and cardiovascular health and the development of cardiovascular diseases CVD. The study focuses on the Chinese population to address limitations seen in previous research that lacked diversity and integration of multi-omics data with environmental factors. Participants will undergo extensive assessments including panvascular and whole-body imaging such as fundus OCT, carotid ultrasound, chest and abdominal CT, cardiac CT, electrocardiograms, and multi-omics profiling genomics, transcriptomics, proteomics, metabolomics. Data on living environments, psychological and cognitive status, clinical medication, surgical records, and health outcomes will also be collected. The study plans to enroll 50,000 adults and follow them over time to create a detailed biological network linking genes and environment to disease. Participants will be followed for up to ten years with annual evaluations of major cardiovascular events and other health outcomes. Imaging and functional assessments of the heart and lungs will be done at least every two years. Questionnaires on lifestyle, anxiety, and cognition will be collected every five years. Safety monitoring includes tracking adverse reactions to contrast agents used in imaging. This long-term follow-up aims to identify key intervention points for preventing and managing cardiovascular diseases.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a half-dose bolus of recombinant staphylokinase r-SAK given before primary percutaneous coronary intervention PCI in patients with acute ST-segment elevation myocardial infarction STEMI. This phase 4, multi-center, randomized, double-blind, placebo-controlled trial aims to determine whether adding r-SAK immediately before PCI improves outcomes compared to placebo within 120 minutes of the procedure. The study is motivated by the need to improve early reperfusion and reduce heart damage in STEMI patients. Participants are randomly assigned to receive either a single intravenous bolus of 5 mg r-SAK over 3 minutes or a placebo injection within 10 minutes after STEMI diagnosis and before PCI. The trial compares these two groups to assess the impact on major adverse cardiovascular events MACE within 90 days. The study also monitors other heart and brain event outcomes, heart function measures, and blood flow grades before and after PCI. During the study, participants undergo assessments including cardiac magnetic resonance imaging, echocardiograms, and blood tests for heart-related biomarkers at specified days up to 360 days after treatment. Researchers observe the occurrence of cardiovascular events, measure heart function, and monitor safety outcomes throughout the trial period. Participants are followed to evaluate both short-term and longer-term effects of the treatment compared to placebo.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Yangxinshi tablets in patients with coronary heart disease combined with cardiac dysfunction. This study aims to determine if adding Yangxinshi tablets to standard treatment can reduce heart-related events, enhance exercise capacity, and improve quality of life and mental health. The trial includes 2708 patients and is a Phase 4 randomized controlled study sponsored by SPH Qingdao Growful Pharmaceutical Co., Ltd. Participants are randomly assigned to one of two groups one group receives conventional treatment plus Yangxinshi tablets 3 tablets taken orally three times a day, while the control group receives conventional treatment alone. Conventional treatment includes drugs such as aspirin, beta-blockers, statins, and others for symptom relief and improving heart outcomes. The treatment continues until a set number of heart-related events occur or the study ends. Throughout the study, participants undergo regular assessments including measurements of heart events, exercise tolerance, heart function tests, blood markers, and mental health questionnaires over an average of three years. Additional evaluations at 24 and 48 weeks include depression and anxiety scales, echocardiography, and exercise testing. The research team closely monitors safety, quality of life, and heart function throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are conducting the IDEAL study, a large, multicenter, prospective, double-blind randomized controlled trial, to evaluate the impact of an artificial intelligence AI model on diagnosing intracranial aneurysms using head CT angiography CTA. The study aims to compare the diagnostic sensitivity and specificity of this AI-assisted approach against a sham AI method, while also assessing patient prognosis and various clinical outcomes. Over 6450 patients scheduled for head CTA will be enrolled across 21 hospitals in China. Participants will be randomly assigned to one of two groups the True-AI group, where radiologists use a deep-learning AI model with high sensitivity to assist in diagnosing intracranial aneurysms, and the Sham-AI group, where radiologists use a similar AI model with very low sensitivity but comparable specificity. Both groups will undergo their usual head CTA scans and diagnoses. The study includes a 12-month follow-up to monitor repeat imaging, clinical follow-up, treatment, and patient outcomes. During the study, patients will have their head CTA images interpreted with either the True-AI or Sham-AI assistance, without knowledge of group assignment by patients or radiologists. Researchers will assess diagnostic accuracy, detection rates of intracranial lesions, workload of CTA interpretation, resource use, hospitalization rates, quality of life measures, functional outcomes, and safety indicators at 3, 6, and 12 months. The primary outcomes focus on diagnostic sensitivity and specificity at 6 months, with secondary outcomes covering broader clinical and patient-centered measures over the follow-up period.
Actively Recruiting
Researchers are conducting an observational study to understand the natural progression of atypical parkinsonian syndromes APS, including Multiple System Atrophy MSA, Dementia with Lewy Bodies DLB, Progressive Supranuclear Palsy PSP, and Corticobasal Degeneration CBD. The study aims to clarify how motor and non-motor symptoms evolve over time and to identify characteristic patterns in imaging that accompany disease progression. The goal is to develop a comprehensive assessment framework and gather clinical and biological data to find early predictive biomarkers for these conditions. No treatments or interventions are applied in this study it is purely observational. Participants diagnosed with one of the APS conditions will be followed to track changes in their symptoms and imaging results over time. The study plans to observe participants for up to 36 months to document the natural course of the diseases. During the study, participants will undergo regular assessments to monitor disease progression, including clinical evaluations and imaging studies. Researchers will collect data to better understand symptom changes and disease markers. This information will help build clinical and biological databases. The total participation duration can be up to three years, during which safety and disease progression will be closely monitored.
Actively Recruiting
This trial focuses on patients aged 70 years or older with resectable stage IIA-IIIB non-small cell lung cancer NSCLC who do not have certain genetic alterations EGFR, ALK, ROS1. Researchers are evaluating a combination of oral paclitaxel solution, immune checkpoint inhibitors, and stereotactic body radiotherapy SBRT as a neoadjuvant treatment before surgery. The study aims to assess safety, tolerability, and preliminary effectiveness of this approach in older adults who may have higher risks from standard therapies. During Phase I, participants receive escalating doses of oral paclitaxel solution 80, 120, 160 mgm on Days 1 and 8 of each cycle, divided into morning and evening doses, combined with an anti-PD-1 or anti-PD-L1 monoclonal antibody and SBRT delivered as 8 Gy per fraction for 3 fractions. Phase II enrolls more participants at the recommended dose to further assess antitumor activity. Participants suitable for surgery after neoadjuvant therapy may undergo radical lung cancer surgery, while others receive definitive radiotherapy. Participants will undergo tumor response assessments through pathology and imaging, surgical evaluation if operable, and long-term follow-up for event-free and overall survival. Researchers will monitor treatment-related adverse events, pathologic complete response, and biomarker changes including immune cells, circulating tumor DNA, and PD-L1 expression. The study duration extends through treatment and follow-up until 2028, with careful safety and efficacy evaluations at multiple timepoints.
1-10 of 12
1